Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert D Knight

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
European Journal of Haematology|March 24, 2009
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myelomaEdward A Stadtmauer, Donna M Weber, Ruben Niesvizky, et al.
Biophysical Journal|June 4, 2021
Myofiber stretch induces tensile and shear deformation of muscle stem cells in their native nicheMohammad Haroon, Jenneke Klein-Nulend, Astrid D Bakker, et al.
Clinical Lymphoma & Myeloma|May 2, 2009
Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event resultsAntonio Palumbo, Patrizia Falco, Antonietta Falcone, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Open Raman Microscopy (ORM): A Modular Hardware and Software Framework for Accessible Raman ImagingKevin T Uning, Henry Brisebois, Conor C Horgan, et al.
The New England Journal of Medicine|November 23, 2007
Lenalidomide plus dexamethasone for relapsed or refractory multiple myelomaMeletios Dimopoulos, Andrew Spencer, Michael Attal, et al.
The New England Journal of Medicine|November 23, 2007
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North AmericaDonna M Weber, Christine Chen, Ruben Niesvizky, et al.
British Journal of Haematology|June 24, 2009
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myelomaChristine Chen, Donna E Reece, David Siegel, et al.
Nature Communications|April 14, 2026
Restorative macrophage-derived RNAseT2 stimulates muscle stem cell fusion via an SLK/N-WASP/actin bundling dependent axisMichéle Weiss-Gayet, Gaëtan Juban, Emmeran Le Moal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2017
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-AnalysisPhilip L McCarthy, Sarah A Holstein, Maria Teresa Petrucci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 23, 2008
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemiaLeslie A Andritsos, Amy J Johnson, Gerard Lozanski, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
European Journal of Haematology|March 24, 2009
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myelomaEdward A Stadtmauer, Donna M Weber, Ruben Niesvizky, et al.
Biophysical Journal|June 4, 2021
Myofiber stretch induces tensile and shear deformation of muscle stem cells in their native nicheMohammad Haroon, Jenneke Klein-Nulend, Astrid D Bakker, et al.
Clinical Lymphoma & Myeloma|May 2, 2009
Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event resultsAntonio Palumbo, Patrizia Falco, Antonietta Falcone, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Open Raman Microscopy (ORM): A Modular Hardware and Software Framework for Accessible Raman ImagingKevin T Uning, Henry Brisebois, Conor C Horgan, et al.
The New England Journal of Medicine|November 23, 2007
Lenalidomide plus dexamethasone for relapsed or refractory multiple myelomaMeletios Dimopoulos, Andrew Spencer, Michael Attal, et al.
The New England Journal of Medicine|November 23, 2007
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North AmericaDonna M Weber, Christine Chen, Ruben Niesvizky, et al.
British Journal of Haematology|June 24, 2009
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myelomaChristine Chen, Donna E Reece, David Siegel, et al.
Nature Communications|April 14, 2026
Restorative macrophage-derived RNAseT2 stimulates muscle stem cell fusion via an SLK/N-WASP/actin bundling dependent axisMichéle Weiss-Gayet, Gaëtan Juban, Emmeran Le Moal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2017
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-AnalysisPhilip L McCarthy, Sarah A Holstein, Maria Teresa Petrucci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 23, 2008
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemiaLeslie A Andritsos, Amy J Johnson, Gerard Lozanski, et al.
Pageof 5